Source link : https://www.newshealth.biz/health-news/nanoliposomal-irinotecan-fails-to-boost-survival-in-treated-advanced-biliary-cancer/
Adding liposome-encapsulated irinotecan to standard chemotherapy failed to improve survival as second-line treatment for advanced biliary cancer, a small randomized study showed. Median progression-free survival (PFS) improved nonsignificantly from 2.3 to 2.6 months with the addition of nanoliposomal irinotecan to fluorouracil and leucovorin. Overall survival (OS) declined slightly from 8.2 months without irinotecan to 6.9 […]
Author : News Health
Publish date : 2024-06-12 18:58:01
Copyright for syndicated content belongs to the linked Source.
Categories